N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b

Abstract

The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R 1 , R 2 , L 1 , L 2 , X, Y, and Y′ are described therein.

1 . A compound of formula I: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof,
 wherein: 
 L 1  is straight or branched C 1 -C 5  alkylene substituted OC 1 -C 6  alkyl; or 
 L 1  is —C(O)—C 1 -C 3 alkylenyl-, 
 R 1  is cycloalkyl, aryl, or heteroaryl, any of which optionally substituted with one or more substituents selected from the group consisting of OH, CN, halogen, —C 1 -C 6 alkylaryl, —O—C 1 -C 6 alkylaryl, O—R 10 , OPO 3   −2 M 2 , OP(O)(OH) 2 , SH, S—R 10 , C 1 -C 5  alkyl, branched alkyl, NH 2 , NHR 10 , NHS(O) 2 R 10 , N(R 10 R 10 ′), and NHCOR 10  where M is a monovalent metal cation; 
 each R 10  and R 10 ′ is independently selected from the group consisting of H; C 1 -C 6  alkyl optionally substituted with one or more substituents selected from the group consisting of OH, O—C 1 -C 5  alkyl, OPO 3   −2 M 2 , OP(O)(OH) 2 , OC(O)alkyl, and OC(O)O-alkyl where M is a monovalent metal cation; and cycloalkyl optionally substituted with one or more substituents selected from the group consisting of OH and O—C 1 -C 5  alkyl provided that no more than one oxygen is attached to any carbon; or R 10  and R 10 ′, together with the nitrogen to which they are attached, may form a heterocycle selected from the group consisting of oxetanyl, azetadinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, and homotropanyl; 
 X is selected from O, S, —S(O)—, and —S(O) 2 —; 
 Y and Y′ are independently H, halogen, or C 1 -C 5  alkyl; 
 L 2  is a bond, —(CH 2 ) n — or —(CHR 11 ) n —; 
 each R 11  is independently selected from the group consisting of H, —C 1 -C 5  alkylenyl-, —CO—C 1 -C 5 alkylenyl-, and -alkylenyl-CO-alkylenyl-; 
 R 2  is phenyl, naphthyl, heteroaryl or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents selected from the group consisting of halogen, OH, C 1 -C 6 alkyl, OR 10 , CN, NH 2 , NHR 10 , N(R 10 )(R 10 ′), -nitro, SH, SR 10 , SOR 10 , SO 2 R 10 , SO 2 NHR 10 , SO 2 N(R 10 )(R 10 ′), CONH 2 , CONR 10 , and CON(R 10 )(R 10 ′); and 
 n is 1, 2, or 3; 
 wherein cycloalkyl is a monocyclic saturated carbon ring containing 3-18 carbon atoms; and 
 wherein heteroaryl is a monocyclic, bicyclic or polycyclic aromatic radical of 5 to 10 ring atoms and containing one or more ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, and when containing two fused rings, the aryl groups may have an unsaturated or partially saturated ring fused with a fully saturated ring. 
 
     
     
         2 . The compound of  claim 1 , wherein L 2  is a bond and R 2  is phenyl optionally substituted with one or more halogen, OH, OR 10 , CN, NH 2 , NHR 10 , N(R 10 )(R 10 ′), SH, SR 10 , SOR 10 , SO 2 R 10 , SO 2 NHR 10 , SO 2 N(R 10 )(R 10 ′), CONH 2 , CONR 10 , CON(R 10 )(R 10 ′). 
     
     
         3 . The compound of  claim 2 , wherein X is O. 
     
     
         4 . The compound of  claim 2 , wherein R 1  is aryl or heteroaryl each of which is substituted with one or more substituents selected from the group consisting of OH, halogen, OR 10 , SH, SR 10 , NH 2 , NHR 10  and NHCOR 10 . 
     
     
         5 . The compound of  claim 2 , wherein Y and Y′ are hydrogen. 
     
     
         6 . A pharmaceutical composition comprising a compound of  claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable carrier. 
     
     
         7 . A method of treating an emotional disorder selected from bipolar disorder, obsessive-compulsive disorder, and depression, the method comprising administering to a subject in need thereof an effective amount of a compound of formula I: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof,
 wherein: 
 L 1  is straight or branched C 1 -C 5  alkylene substituted OC 1 -C 6  alkyl; or 
 L 1  is —C(O)—C 1 -C 3 alkylenyl-, 
 R 1  is cycloalkyl, aryl, or heteroaryl, any of which optionally substituted with one or more substituents selected from the group consisting of OH, CN, halogen, —C 1 -C 6 alkylaryl, —O—C 1 -C 6 alkylaryl, O—R 10 , OPO 3   −2 M 2 , OP(O)(OH) 2 , SH, S—R 10 , C 1 -C 5  alkyl, branched alkyl, NH 2 , NHR 10 , NHS(O) 2 R 10 , N(R 10 )(R 10 ′), and NHCOR 10  where M is a monovalent metal cation; 
 each R 10  and R 10 ′ is independently selected from the group consisting of H; C 1 -C 6  alkyl optionally substituted with one or more substituents selected from the group consisting of OH, O—C 1 -C 5  alkyl, OPO 3   −2 M 2 , OP(O)(OH) 2 , OC(O)alkyl, and OC(O)O-alkyl where M is a monovalent metal cation; and cycloalkyl optionally substituted with one or more substituents selected from the group consisting of OH and O—C 1 -C 5  alkyl provided that no more than one oxygen is attached to any carbon; or R 10  and R 10 ′, together with the nitrogen to which they are attached, may form a heterocycle selected from the group consisting of oxetanyl, azetadinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, and homotropanyl; 
 X is selected from O, S, —S(O)—, and —S(O) 2 —; 
 Y and Y′ are independently H, halogen, or C 1 -C 5  alkyl; 
 L 2  is a bond, —(CH 2 ) n — or —(CHR 11 ) n —; 
 each R 11  is independently selected from the group consisting of H, —C 1 -C 5  alkylenyl-, —CO—C 1 -C 5 alkylenyl-, and -alkylenyl-CO-alkylenyl-; 
 R 2  is phenyl, naphthyl, heteroaryl or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents selected from the group consisting of halogen, OH, C 1 -C 6 alkyl, OR 10 , CN, NH 2 , NHR 10 , N(R 10 )(R 10 ′), -nitro, SH, SR 10 , SOR 10 , SO 2 R 10 , SO 2 NHR 10 , SO 2 N(R 10 )(R 10 ′), CONH 2 , CONR 10 , and CON(R 10 )(R 10 ′); and 
 n is 1, 2, or 3; 
 wherein cycloalkyl is a monocyclic saturated carbon ring containing 3-18 carbon atoms; and 
 wherein heteroaryl is a monocyclic, bicyclic or polycyclic aromatic radical of 5 to 10 ring atoms and containing one or more ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, and when containing two fused rings, the aryl groups may have an unsaturated or partially saturated ring fused with a fully saturated ring. 
 
     
     
         8 . The method of  claim 7 , wherein the emotional disorder is selected from bipolar disorder, and obsessive-compulsive disorder. 
     
     
         9 . The method of  claim 8 , wherein the bipolar disorder is bipolar depression. 
     
     
         10 . The method of  claim 7 , wherein the emotional disorder is major depressive disorder or depression. 
     
     
         11 . The method of  claim 7 , wherein the emotional disorder is refractory or treatment resistant depression. 
     
     
         12 . The method of  claim 7 , wherein L 2  is a bond and R 2  is phenyl optionally substituted with one or more halogen, OH, OR 10 , CN, NH 2 , NHR 10 , N(R 10 )(R 10 ′), SH, SR 10 , SOR 10 , SO 2 R 10 , SO 2 NHR 10 , SO 2 N(R 10 )(R 10 ′), CONH 2 , CONR 10 , CON(R 10 )(R 10 ′). 
     
     
         13 . The method of  claim 12 , wherein X is O. 
     
     
         14 . The method of  claim 12 , wherein R 1  is aryl or heteroaryl each of which is substituted with one or more substituents selected from the group consisting of OH, halogen, OR 10 , SH, SR 10 , NH 2 , NHR 10  and NHCOR 10 . 
     
     
         15 . The method of  claim 12 , wherein Y and Y′ are hydrogen.